

# Clinical study to evaluate the efficacy of probiotics in reducing weight in Asian subjects

<b>Submission date</b> 12/02/2025	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 13/02/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 12/02/2025	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Obesity is a complex condition that goes beyond just excess weight; it is linked to various health problems and is becoming a growing global issue. These related conditions include type 2 diabetes, high blood pressure, breathing difficulties, joint problems, circulation disorders, and even depression. All of these can seriously affect overall health and increase the risk of illness and death.

Research has shown that an imbalance in gut bacteria (microbiota) can negatively impact weight control, energy balance, and how the body processes fats and sugars.

In recent decades, obesity rates among Chinese adults have risen significantly. Synbalance S.r.l., the sponsor of this study, aims to evaluate whether a food supplement can help overweight or obese Asian individuals lose weight. The study will also assess whether the supplement can improve quality of life and positively affect cholesterol, triglycerides, glycemia, insulin levels, fat distribution, diabetes-related indices, and its action on the fecal microbiome.

A randomized, double-blind, placebo (dummy) -controlled trial with 66 healthy overweight/mild obese male and female participants with large waist will assess the efficacy of the food supplement containing probiotics, compared to placebo. Participants will take the supplement daily, with evaluations at baseline, 56, and 84 days, alongside adverse event monitoring.

### Who can participate?

Healthy male and female subjects aged between 18 and 45 years, overweight/mild obese and with large waist.

### What does the study involve?

Participants will be asked to attend clinic visits at screening, at baseline and after 56 and 84 days of treatment.

During the screening visit, the medical doctor will inform the participants about the trial procedure, risks, and benefits. Only participants giving their informed consent will be enrolled in the study.

All the measurements/assessments performed during the visits will be carried out using minimally invasive procedures and blood samples will be taken by a professional nurse.

What are the possible benefits and risks of participating?

Risks associated with the product intake are considered from low to very low, in absence of allergy/intolerances to product ingredients; other ingredients in the product formula are commonly used in dietary supplements.

The potential benefits associated with the use of the product are related to a reduction of body weight and an improvement in quality of life of overweight/mild obese subjects.

Where is the study run from?

Complife Beijing Testing Technology Co., Ltd, China

When is the study starting and how long is it expected to run for?

July 2024 to July 2025

Who is funding the study?

SynBalance Srl (Italy)

Who is the main contact?

Roberta Villa, roberta.villa@complifegroup.com

## Contact information

### Type(s)

Public, Scientific

### Contact name

Dr Roberta Villa

### Contact details

Viale Indipendenza, 11

Pavia (PV)

Italy

27100

+39 38225504

roberta.villa@complifegroup.com

### Type(s)

Principal investigator

### Contact name

Dr Achirpita Curti

### Contact details

Nutratch S.r.l. - Via Francesco Todaro 20/22

Rende (CS)

Italy

Italy

+39 378 303 7302

nutratch@nutratchtesting.com

## Additional identifiers

**Protocol serial number**

PROBESI 2025

## Study information

**Scientific Title**

Clinical evaluation of the weight loss efficacy of a food supplement: a randomized double-blind placebo-controlled study on Asian subjects

**Acronym**

SLIMASIA

**Study objectives**

There will be a positive effect of a food supplement in reducing body weight in overweight /mildly obese Asian subjects.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 22/11/2024, Comitato Etico Indipendente presso la società Derming S.r.l. (Independent Ethics Committee operating at Dermings s.r.l.) (Via Morone, 6, Milano, 20121, Italy; +39 2 23183475; adele.sparavigna@derming.com), ref: V221124

**Study design**

Double blind randomized parallel-group placebo-controlled

**Primary study design**

Interventional

**Study type(s)**

Treatment, Safety, Efficacy

**Health condition(s) or problem(s) studied**

Overweight/mild obese

**Interventions**

The product under study consists of a food supplement containing probiotics.

Half of the recruited subjects will be randomized to receive the active product and half of the recruited subjects will be randomized to receive the placebo product.

A restricted randomization list will be generated by the study director using PASS 11 software (PASS, LLC. Kaysville, UT, USA) and the appropriate randomization algorithm ("Wey's urn") and stored in a safe place.

An independent technician dispenses the products according to the randomization list.

The study will be double blind: subjects, investigator and collaborators are kept masked to products assignment.

Products will be supplied in the same packaging without any obvious differences among products.

Subjects will take the assigned food supplement (once a day) for 84 days.

## Intervention Type

Supplement

### Primary outcome(s)

1. Body weight (kg) at baseline, and after 56 days and 84 days of treatment
2. Body Mass Index (kg/m<sup>2</sup>) at baseline, and after 56 days and 84 days of treatment
3. Waist circumference (cm) at baseline, and after 56 days and 84 days of treatment
4. Hip circumference (cm) at baseline, and after 56 days and 84 days of treatment

### Key secondary outcome(s)

1. Obesity-related Quality of Life (ORWELL-97) at baseline, and after 56 days and 84 days of treatment
2. Blood parameters at baseline, and after 56 days and 84 days of treatment:
  - 2.1. Total Cholesterol (mmol/l)
  - 2.2. HDL cholesterol (mmol/l)
  - 2.3. LDL cholesterol (mmol/l)
  - 2.4. Triglycerides (mmol/l)
  - 2.5. Fasting Insulin (pmol/l)
  - 2.6. Fasting Glucose (mmol/l)
  - 2.7. HbA1c (mmol/l)
3. Fecal microbiome analysis at baseline, and after 84 days of treatment
4. Conicity index (CI) at baseline, and after 56 days and 84 days of treatment
5. Visceral Adiposity Index (VAI) at baseline, and after 56 days and 84 days of treatment
6. HOMA index (Homeostasis Model Assessment) at baseline, and after 56 days and 84 days of treatment
7. Self-evaluation questionnaire (polytomous question with four possible answers) after 84 days of treatment
8. Incidence and nature of Adverse Event (AE) and Serious Adverse Event (SAE) after 56 days and 84 days of treatment

### Completion date

31/07/2025

## Eligibility

### Key inclusion criteria

1. Healthy male and female subjects
2. Asian ethnicity
3. Aged between 18 and 45 years (including extremes)
4. Subjects overweight/mild obese (BMI between 26 and 31.9 kg/m<sup>2</sup>)\*
5. Subjects with large waist (waistline >80 centimetres for women and >85 centimetres for men)
6. Subjects certifying the truthfulness of the personal data disclosed to the investigator
7. Subjects able to understand the language used in the investigation center and the information given by the investigator
8. Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
9. Commitment not to change the daily routine or the lifestyle\*\*
10. Stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study

11. Subject is under effective contraception (oral/not oral) therapy if fertile
12. Subjects informed about the test procedures who have signed a consent form and privacy policy

\*According to "Health standards of the People's Republic of China", National Health and Family Planning Commission of the People's Republic of China:

Classification BMI

Obese BMI  $\geq 28.0$  kg/m<sup>2</sup>

Overweight  $24.0$  kg/m<sup>2</sup>  $\leq$  BMI  $< 28.0$  kg/m<sup>2</sup>

Normal  $18.5$  kg/m<sup>2</sup>  $\leq$  BMI  $< 24.0$  kg/m<sup>2</sup>

Underweight BMI  $< 18.5$  kg/m<sup>2</sup>

\*\* Subjects will keep a food diary to ensure that they do not change their eating habits during the study

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Upper age limit**

45 years

### **Sex**

All

### **Key exclusion criteria**

1. Subjects who do not meet the inclusion criteria
2. Subjects participating or planning to participate in other clinical trials
3. Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
4. Subjects who are currently using food supplement(s) and/or topical products with the same activity as the study product, or who haven't observed an adequate washout period since stopping use (at least one month)
5. Subjects admitted to a health or social facility
6. Subjects planning a hospitalization during the study
7. Subjects not able to be contacted in case of emergency
8. Subjects deprived of freedom by administrative or legal decision or under guardianship
9. Subjects with a history of drug, alcohol, and other substance abuse
10. Alimentary/Eating disorders (i.e., bulimia, psychogenic eating disorders, etc.)
11. Smokers
12. Subject breastfeeding, pregnant, or not willing to take necessary precautions to avoid pregnancy during the study (for women of childbearing potential)
13. Subjects with any acute, chronic, or progressive disease or skin condition that may interfere with the study data or that the investigator considers dangerous to the subject or incompatible

with the requirements of the study

14. Subjects that have food intolerances or food allergies or allergy to ingredients of the study product or allergy to any of the ingredients in the product under investigation

15. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator

**Date of first enrolment**

14/02/2025

**Date of final enrolment**

28/03/2025

## **Locations**

**Countries of recruitment**

China

Italy

**Study participating centre**

**Complife Beijing Testing Technology Co., Ltd**

Beizhan North Street N.17, Room 902- Xicheng District

Beijing

China

100089

**Study participating centre**

**Nutratch S.r.l.**

Via Francesco Todaro 20/22

Rende (CS)

Italy

87036

## **Sponsor information**

**Organisation**

SynBalance srl

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

SynBalance srl

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

Raw data will be stored on the Complife Beijing Testing Technology Co. and Nutratch server. A backup copy of the raw data will be also in a cloud-based backup server. Tables containing the raw data (output of the measurements) will be also included in the study report and shared with the study sponsor by a pdf file electronically signed. The raw data will be stored for a minimum period of 10 years on Complife servers. In the raw data tables, subjects are identified by a means of a code generated by the Complife volunteer's management software. The code is composed of a letter, four digits, and a letter. Access to the study's raw data is allowed by application only to the study director and the person designated by him to elaborate on the raw data.

Elaboration of the raw data includes descriptive statistics and inferential analysis.

### **IPD sharing plan summary**

Stored in non-publicly available repository, Published as a supplement to the results publication